Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVLP with Doxorubicin for Sarcoma Lung Metastases
NCT02811523Phase 1Recruiting
- Sponsor
- University Health Network
- Start
- Feb 2016
- Primary completion
- Sep 2030
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label trial of doxorubicin in bone sarcoma and soft tissue sarcoma (STS) (4 arms), sponsored by University Health Network. Primary endpoints: Safety of IVLP at selected dose levels by acute lung injury findings up to 2 years and Maximal tolerated dose up to 2 years. Started Feb 2016; status: recruiting.
02
Drugs
doxorubicin
03
Conditions
bone sarcomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02811523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02811523.